Cardiovascular Genomics

Cardiovascular genomics has moved from research curiosity to clinical decision tool. Sessions cover polygenic risk scores in primary prevention, monogenic cardiomyopathy and channelopathy diagnostics, familial hypercholesterolaemia detection, clonal haematopoiesis as a CV risk modifier, and the first in-vivo CRISPR base-editing programmes targeting PCSK9, TTR and Lp(a). Discussion includes counselling and consent for inherited disease, family-screening models, and the regulatory pathway for durable single-dose genome editing. The track convenes geneticists, cardiologists and the gene-therapy industry.